BioCryst Pharmaceuticals (FRA:BO1) Change In Payables And Accrued Expense : €-31.6 Mil (TTM As of Mar. 2024)

View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Change In Payables And Accrued Expense?

BioCryst Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was €-41.0 Mil. It means BioCryst Pharmaceuticals's Accounts Payable & Accrued Expense declined by €41.0 Mil from Dec. 2023 to Mar. 2024 .

BioCryst Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €-15.4 Mil. It means BioCryst Pharmaceuticals's Accounts Payable & Accrued Expense declined by €15.4 Mil from Dec. 2022 to Dec. 2023 .

BioCryst Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for BioCryst Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Change In Payables And Accrued Expense Chart

BioCryst Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

13.32

19.83

38.57

-21.11

-15.41

BioCryst Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-25.43	-0.17	-8.68	18.22	-41.00

BioCryst Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-31.6 Mil.

BioCryst Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCryst Pharmaceuticals (FRA:BO1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (FRA:BO1) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

BCRX:USA BCRX:Mexico BO1:Germany

Address

4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703

Website

http://www.biocryst.com

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

BioCryst Pharmaceuticals (FRA:BO1) Headlines

No Headlines